First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis

BACKGROUND: The ARROW study demonstrated favorable clinical efficacy and safety of pralsetinib (PRL) in treating rearranged during transfection (RET) fusion positive non-small cell lung cancer (NSCLC) in clinical trials. However, due to the high cost of PRL, evaluating its cost-effective characteris...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wenjie, Huo, Gengwei, Li, Mengjie, Chen, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579832/
https://www.ncbi.nlm.nih.gov/pubmed/37854153
http://dx.doi.org/10.21037/tlcr-23-469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579832/
https://www.ncbi.nlm.nih.gov/pubmed/37854153
http://dx.doi.org/10.21037/tlcr-23-469

Ejemplares similares